---
title: "Kiromic Biopharma (KRBP.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KRBP.US.md"
symbol: "KRBP.US"
name: "Kiromic Biopharma"
industry: "Biotechnology"
datetime: "2026-03-05T08:44:38.775Z"
locales:
  - [en](https://longbridge.com/en/quote/KRBP.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KRBP.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KRBP.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/KRBP.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/KRBP.US.md)


# Kiromic Biopharma (KRBP.US)

## Company Overview

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company’s lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-small cell lung cancer. It also develops Isocel, which is clinical trial in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; Procel, which is in clinical trial in combination with low-dose radiation to treat PD-L1 positive solid malignancies; ALEXIS-ISO-1, which is in clinical trial to evaluate Isocel in patients with Mesothelin Isoform 2 positive solid malignancies; and ALEXIS-PRO-1, which is in clinical trial to evaluate Procel in patients with PD-L1 positive solid malignancies. It has a license agreement with Longwood University.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.05 | 79 | - | - | - |
| PB | -0.02 | 497 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/KRBP.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/KRBP.US/norm.md)
- [Related News](https://longbridge.com/en/quote/KRBP.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/KRBP.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**